GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-01-21 08:00 |
GENFIT: 2020 Financial Calendar
|
English | 162.3 KB | ||
| 2020-01-21 08:00 |
GENFIT ANNONCE SON CALENDRIER FINANCIER POUR 2020
|
French | 130.4 KB | ||
| 2020-01-10 22:15 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 159.0 KB | ||
| 2020-01-10 22:15 |
GENFIT: 2019 Half-Year Report of Liquidity Contract with Crédit Industriel et …
|
English | 159.7 KB | ||
| 2019-11-28 18:00 |
GENFIT : Résultats de l’Assemblée Générale Ordinaire et Extraordinaire du 27 no…
|
French | 224.3 KB | ||
| 2019-11-28 18:00 |
GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’ Meeting of Nove…
|
English | 148.8 KB | ||
| 2019-11-26 08:46 |
GENFIT : Issue positive du DSMB à 42 mois, recommandant la poursuite de l’étude…
|
French | 223.8 KB | ||
| 2019-11-26 08:46 |
GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOL…
|
English | 273.8 KB | ||
| 2019-11-10 14:00 |
GENFIT Announces Results of NIS4, an Investigational Non-Invasive NASH Diagnost…
|
English | 399.4 KB | ||
| 2019-11-10 14:00 |
GENFIT : Résultats d’une étude avec NIS4, outil de diagnostic expérimental non …
|
French | 409.1 KB | ||
| 2019-10-31 07:45 |
GENFIT : Nouvelles données présentées au Liver Meeting 2019 de l’AASLD
|
French | 462.3 KB | ||
| 2019-10-31 07:45 |
GENFIT Announces New Data to be Presented at AASLD Liver Meeting 2019
|
English | 485.1 KB | ||
| 2019-10-30 21:15 |
GENFIT : Information financière du troisième trimestre 2019
|
French | 207.5 KB | ||
| 2019-10-30 21:15 |
GENFIT: Reports Third Quarter 2019 Financial Information
|
English | 189.5 KB | ||
| 2019-10-21 23:15 |
GENFIT : Assemblée générale ordinaire et extraordinaire du 27 novembre 2019 – m…
|
French | 12.4 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
